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Abstract
Background: Cardiac impairment is associated with high morbidity and mortality in immunoglobulin light chain (AL)
type amyloidosis, for which early identification and risk stratification is vital. For myocardial tissue characterization, late
gadolinium enhancement (LGE) is a classic and most commonly performed cardiovascular magnetic resonance (CMR)
parameter. T1 mapping with native T1 and extracellular volume (ECV) are recently developed quantitative parameters.
We aimed to investigate the prognostic value of native T1, ECV and LGE in patients with AL amyloidosis.
Methods: Eighty-two patients (55.5 ± 8.5 years; 52 M) and 20 healthy subjects (53.2 ± 11.7 years; 10 M) were
prospectively recruited. All subjects underwent CMR with LGE imaging and T1 mapping using a Modified Look-Locker
Inversion-recovery (MOLLI) sequence on a 3 T scanner. Native T1 and ECV were measured semi-automatically using a
dedicated CMR software. The left ventricular (LV) LGE pattern was classified as none, patchy, and global groups. Global
LGE was considered when there was diffuse, transmural LGE in more than half of the short axis images. Follow-up was
performed for all-cause mortality using Cox proportional hazards regression analysis and Kaplan-Meier survival curves.
Results: The patients demonstrated an increase in native T1 (1438 ± 120 ms vs. 1283 ± 46 ms, P= 0.001) and ECV (43.9 ± 10.
9% vs. 27.0 ± 1.7%, P= 0.001) compared to healthy controls. Native T1, ECV and LGE showed significant correlation with Mayo
Stage, and ECV and LGE showed significant correlation with echocardiographic E/E’ and LV ejection fraction. During the
follow-up for a median time of 8 months, 21 deaths occurred. ECV≥ 44.0% (hazard ratio [HR] 7.249, 95% confidence interval
(CI) 1.751–13.179, P= 0.002) and global LGE (HR 4.804, 95% CI 1.971–12.926, P= 0.001) were independently prognostic for
mortality over other clinical and imaging parameters. In subgroups with the same LGE pattern, ECV≥ 44.0% remained
prognostic (log rank P= 0.029). Median native T1 (1456 ms) was not prognostic for mortality (Tarone-Ware, P= 0.069).
Conclusions: During a short-term follow-up, both ECV and LGE are independently prognostic for mortality in AL amyloidosis.
In patients with a similar LGE pattern, ECV remained prognostic. Native T1 was not found to be a prognostic factor.
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Background
Immunoglobulin light chain (AL) type amyloidosis is
characterized by monoclonal plasma cells and the depos-
ition of insoluble fibrils formed by immunoglobulin light
chains in various organs [1]. In approximately two-thirds
of AL-type amyloidosis patients there is cardiac impair-
ment at diagnosis, which is a major contributor to mor-
tality [2]. Thus, early identification and risk stratification
is of vital importance for timely clinical intervention that
may improve the patients’ prognosis. Current predictors
of survival, such as serum biomarkers [3–5], electrocar-
diogram (ECG) [6], cardiac morphology and functional
parameters [7–10] rely on measuring surrogates rather
than direct markers of interstitial expansion.
Cardiovascular magnetic resonance (CMR) imaging
with late gadolinium enhancement (LGE) is the most
commonly performed non-invasive protocol for myocar-
dial tissue characterization in a wide spectrum of cardio-
myopathies. A typical pattern of global, predominately
subendocardial LGE, serves not only as a diagnostic
marker for cardiac AL amyloidosis but also as a prognos-
tic marker for mortality [11–14]. However, because the
recognition of LGE lesions involves delineation of abnor-
mal tissue from normal tissue, early identification of mild
cases can easily be missed in cardiac AL amyloidosis and
other diffuse infiltrative cardiomyopathies [15–17].
Myocardial CMR T1 mapping methods are used for na-
tive (i.e., without use of gadolinium-based agents) and for
post-contrast T1 measurements. In combination with the
hematocrit, pre- and post-contrast measurements enable
the quantification of the extracellular volume fraction
(ECV). Native myocardial T1 values reflect a composite
signal from both the intracellular (predominantly myo-
cytes) and extracellular compartments [18–20]. Previous
studies have shown that different sequences and field
strengths yielded different native T1 and ECV values [21–
24]. To date, only one study has examined the utility of a
shortened Modified Look-Lockers Inversion-recovery
(shMOLLI) sequence at 1.5 T to assess the prognostic
value of native T1 and ECV in AL amyloidosis [25].
However, this study did not concurrently assess the utility
of LGE in this population. In the present study, we exam-
ined a Chinese population with AL amyloidosis using a
3 T scanner with a MOLLI sequence and compared the
prognostic value of T1 mapping parameters with LGE.
This method of analysis of the prognostic values of native
T1 and ECV for mortality in AL amyloidosis and its com-
parison with LGE have not been reported previously.
Methods
Study subjects
This prospective study was approved by the Institutional
Ethnics Committee for Human Research at Peking Union
Medical College Hospital (Beijing, China). All participants
were required to provide written informed consent prior to
recruitment. AL amyloidosis patients who were referred for
CMR imaging at Peking Union Medical College Hospital
between August 1, 2014 and August 31, 2016 were included
in the study. Approximately 20% of the patients who had
contraindications either to CMR imaging (i.e., CMR-
incompatible devices) or contrast administration (i.e., esti-
mated glomerular filtration rate < 30 ml/min) were excluded.
Eighty-two AL amyloidosis patients (55.5 ± 8.5 years; 52
male) were consecutively recruited. All patients had biopsy
evidence of AL amyloidosis with positive Congo red stain
and light chain deposition confirmed by immunohisto-
chemistry, immunofluorescence or mass spectrometer.
The assays were performed in the tissues listed as follows:
kidney (n = 29), myocardium (n = 19), bone marrow (n =
7), fat (n = 7), tongue (n = 7), liver (n = 4), upper gastro-
intestinal tract (n = 3), buccal mucosa (n = 3), lung (n = 1),
rectum (n = 1) and skin (n = 1). All patients underwent
laboratory examination of the cardiac biomarkers Tropo-
nin I (cTnI) and N-terminal pro-B-type natriuretic peptide
(NT-proBNP), serum immunoglobulin free light chain
difference (dFLC) at baseline and were categorized based
on revised Mayo Stage published in 2012 [5]. All patients
underwent transthoracic echocardiography (TTE) at
baseline and the E: E′ ratio and E: A ratio were calculated
to assess the left ventricular (LV) diastolic function. A
hematologist and a cardiologist, both of whom were
blinded to the results of CMR imaging, recorded the
results of Mayo Stage and TTE, respectively.
Twenty healthy subjects (53.2 ± 11.7 years; 10 male)
with normal CMR imaging results were recruited, who
had neither history nor symptoms of cardiovascular
disease or diabetes mellitus.
CMR scanning protocol
CMR was performed on a 3 T whole-body scanner (MAG-
NETOM Skyra, Siemens Healthineers, Erlangen, Germany).
The system is capable of operating at a maximum slew rate
of 200 mT/m/ms and a maximum gradient strength of 45
mT/m. An 18-element body matrix coil and a 32-element
spine array coil were used for data acquisition. A four-lead
vector cardiogram was used for ECG gating.
Two-dimensional (2D) scout images in transversal, coronal
and sagittal views were first acquired for localization of the
heart. The cine images were acquired with an ECG-gated 2D
balanced steady-state free precession (bSSFP) sequence
during multiple breath holds. To evaluate cardiac motion
and function, two-, three-, and four-chamber long-axis and
10–12 short-axis slices covering the LV were acquired. The
key parameters were as follows: repetition time (TR)/echo
time (TE), 3.3/1.43 msec; flip angle (FA), 55°–70°; voxel size,
1.6 × 1.6 × 6.0 mm; temporal resolution, 45.6 msec; band-
width, 962 Hz/pixel. Native and 15–20 min post-contrast T1
mapping were acquired using a MOLLI sequence in identical
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imaging locations, including a four-chamber long-axis slice
and three short-axis slices (apex, mid-ventricular, and basic)
[26]. Acquisition schema 5(3)3 and 4(1)3(1)2 were used for
pre-contrast and post-contrast T1 mapping, respectively. To
generate pixel-wise myocardial T1 maps, single-shot-bSSFP
images were acquired at different inversion times and regis-
tered prior to a non-linear least-square curve fitting [27, 28].
The other parameters included: TR/TE/flip angle, 2.7 ms/
1.12 ms/20°; voxel size, 1.4 × 1.4 × 8.0 mm. LGE images were
collected by a 2D phase-sensitive inversion-recovery (PSIR)
gradient-echo pulse sequence with breath-hold. Parameters
of the sequence were as follows: TR/TE/flip angle, 5.2 ms/
1.96 ms/20°; voxel size, 1.4 × 1.4 × 8.0 mm.
CMR image analysis
CMR images were independently analyzed by two experi-
enced radiologists. The LV LGE pattern was classified into
three groups referred to Araoz Criteria [11] and Moon
Criteria [12]: No LGE, when there were no areas of LGE;
Patchy LGE, when there were discrete areas of LGE, or
there were diffuse areas of LGE in less than half of the
short axis images; Global LGE, when there was diffuse,
transmural LGE in more than half of the short axis
images. Discrepancies were resolved in consensus during
a joint evaluation with a third radiologist.
Cardiac function, native T1 and ECV were measured
semi-automatically using a dedicated CMR software cvi42
(version 5.3, Circle Cardiovascular Imaging, Calgary,
Canada). Standard parameters of cardiac structure (i.e.,
inter-ventricular septum thickness, ventricle volume, LV
mass and left atrium area with indexing for body surface
area) and ventricle ejection fraction were measured by
contouring the endocardium and epicardium on long-axis
and short axis cine images at the end-systolic and end-
diastolic stage. Native T1 and ECV of the 16 American
Heart Association (AHA) segments and global LV were
measured, by contouring the endocardium and epicardium
and indicating the inter-ventricular septum on pre-contrast
and post-contrast T1 mapping images with indexing for the
hematocrit. Global LV native T1 and ECV were used for
further analysis. The average values of native T1 and ECV
measured by the two radiologists were used.
Clinical follow-up
A physician blinded to the results of CMR imaging
conducted the telephone and clinical follow-up each month.
Unless the outcome was death from any cause, patients were
censored at the end of the study. If patients were lost to
follow-up, their last clinic visit record was used. A follow-up
CMR scan was performed after a complete standard course
of chemotherapy, with an interval of about approximately
one year.
Statistical analysis
Statistical analysis was performed using SPSS Statistics
(version 21.0, International Business Machines, Inc.,
Armonk, New York, USA) and R programming language
for statistical computing (version 3.0.1, The R Foundation
for Statistical Computing). The agreement between two ob-
servers was assessed using the interclass correlation
coefficient. Correlation between native T1 and ECV with
continuous variables or categorical variables was assessed
using the Pearson’s r correlation or Spearman ρ correlation,
respectively. Comparison between groups and the control
was performed by one-way analysis of variance (ANOVA)
with post-hoc Bonferroni correction. Statistical significance
was defined as P < 0.05.
Survival was evaluated with Cox proportional hazards
regression analysis, providing estimated hazard ratios
(HR) with 95% confidence intervals (CI) and Kaplan-
Meier curves. All variables were first analyzed with univar-
iate Cox regression. Multivariate models were then used
to evaluate the independent prognostic value of native T1,
ECV or LGE above other clinically and statistically signifi-
cant covariates. The median value of native T1 and ECV
was used as cut-off values. The Harrell’s C statistic was
calculated for different models.
Results
Baseline characteristics and clinical outcome
Table 1 summarizes the characteristics of AL amyloidosis
patients and healthy controls at baseline. At the time of
CMR scanning, 9 (11%) patients had received triple chemo-
therapy for the first time with thalidomide or bortezomib,
cyclophosphamide and dexamethasone (BCD or TCD), 2
(2%) had received autologous stem cell transplant (ASCT)
and 71 (87%) had not received any chemotherapy. During
the follow-up, 59 (83%) untreated patients received
standardized treatment with chemotherapy or ASCT, and
the rest did not receive any chemotherapy because of the
expense or for personal or other reasons. At the time of last
follow-up, 61 (74%) patients were alive, with a survival
probability of approximately 75.6% at median follow-up
time (8 months). Two patients were lost to follow-up. The
follow-up time of one patient (female; 52 years; Mayo Stage,
III; LVEF, 52.5%; native T1, 1575 ms; ECV, 51.4%; LGE
pattern, global) was 5 months, and the other (male; 68 years;
Mayo Stage, II; LVEF, 55.5%; native T1, 1512 ms; ECV,
41.6%; LGE pattern, global) was 18 months.
Clinical and biochemical markers of severity
All continuous variables were normally distributed (Kolmo-
gorov-Smirnov test) and presented as the mean ± SD, except
for cTnI, NT-proBNP and dFLC, which were log
transformed for bivariate testing and presented as medians
(quartiles 1-quartiles 3). As shown in Tables 1, 30 (37%), 24
(29%), 23 (28%) and 5 (6%) patients were classified under
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NYHA Classification I, II, III and IV, respectively. Patients
showed an increase in cTnI (0.043 [0.015–0.146] μg/L vs.
0.000 [0.000–0.040] μg/L, P= 0.024) and NT-proBNP (2056
[348–6096] pg/mL vs. 0 [0–23] pg/mL, P= 0.001) compared
to healthy controls. There were 22 (27%), 18 (22%), 29 (35%)
and 13 (16%) patients in Mayo Stage I, II, III and IV,
respectively. Table 2 summarizes the univariate and
multivariate Cox proportional hazard analysis of overall
survival in all patients. The following were significantly
associated with total mortality in univariate analysis:
age (HR 1.059, 95% CI 1.008–1.112, P = 0.023), NYHA
Classification (HR 2.534, 95% CI 1.581–4.062, P =
0.001), log (cTnI) (HR 2.568, 95% CI 1.204–5.477, P =
0.015), log (NT-proBNP) (HR 3.122, 95% CI 1.501–
6.496, P = 0.002), Mayo Stage (HR 2.111, 95% CI 1.323–
3.368, P = 0.002) and E/E’ (HR 1.089, 95% CI 1.012–
1.110, P = 0.045).
CMR structural and functional parameters
As shown in Tables 1 and 2, AL amyloid patients dem-
onstrated a decrease in LV end-diastolic volume index
(LVEDVi) (58.3 ± 16.0 ml/m2 vs. 74.5 ± 17.1 ml/m2, P =
0.001) and LV ejection fraction (LVEF) (63.3 ± 14.6% vs.
70.3 ± 8.7%, P = 0.043), as well as an increase in indexed
LV mass index (93.5 ± 29.0 g/m2 vs. 65.2 ± 15.3 g/m2, P
= 0.001) and inter-ventricular septal thickness (15.4 ±
4.0 mm vs. 10.5 ± 2.0 mm, P = 0.001) compared to
healthy controls. Univariate analysis showed that LVEF
(HR 0.961, 95% CI 0.936–0.986, P = 0.003) and septal
thickness (HR 1.132, 95% CI 1.040–1.232, P = 0.004)
were significant predictors of mortality.
LGE, native T1 and ECV
Representative examples of LGE pattern, native T1 and
ECV values from a healthy subjects and AL amyloid







Male/female 52/30 10/10 0.27
Age (years) 55.5 ± 8.5 53.2 ± 11.7 0.30
NYHA (I/II/III/IV) 30/24/23/5 – –
cTnI (μg/L) 0.043 (0.015–0.146) 0.000 (0.000–0.040) 0.024
NT-proBNP (pg/mL) 2056 (348–6096) 0 (0–23) 0.001
dFLC (mg/L) 138.0 (46.0–391.5) – –
Mayo Stage (I/II/III/IV) 22/18/29/13 – –
Creatinine (umol/L) 87.3 ± 21.6 74.9 ± 15.3 0.21
HTN/CHD/DM/Af 16/6/3/2 – –
Therapy (BCD/TCD/ASCT) 5/4/2 – –
Echocardiography
E/A 1.3 ± 0.7 – –
E/E’ 16.8 ± 8.3 – –
Cardiac MR
Indexed LVEDV (ml/m2) 58.3 ± 16.0 74.5 ± 17.1 0.001
Indexed LVESV (ml/m2) 22.1 ± 12.4 21.5 ± 8.1 0.79
LVEF (%) 63.3 ± 14.6 70.3 ± 8.7 0.043
Left atrium area (cm2) 21.4 ± 5.0 20.6 ± 5.0 0.52
Indexed left ventricle mass (g/m2) 93.5 ± 29.0 65.2 ± 15.3 0.001
Septal thickness (mm) 15.4 ± 4.0 10.5 ± 2.0 0.001
LGE (no/patchy/global) 26/18/38 – –
Native T1 (ms) 1438 ± 120 1283 ± 46 0.001
ECV (%) 43.9 ± 10.9 27.0 ± 1.7 0.001
All continuous variables are presented as mean ± SD, except for cTnI, NT-proBNP and dFLC, which are presented as medians (quartiles 1-quartiles 3). cTnI Cardiac
Troponin I, NT-proBNP N-terminal pro-B-type natriuretic peptide, dFLC Serum immunoglobulin free light chain difference, NYHA New York Heart Association, HTN
Hypertension, CHD Coronary artery heart disease, DM Diabetes mellitus, Af Atrial fibrillation, BCD Bortezomib, cyclophosphamide and dexamethasone, TCD
Thalidomide, cyclophosphamide and dexamethasone, ASCT Autologous stem cell transplant, MR Magnetic resonance, LVEDV Left ventricle end-diastolic volume,
LVESV Left ventricle end-systolic volume, LVEF Left ventricle ejection fraction, LGE Late gadolinium enhancement, ECV Extracellular volume
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patients with different disease burdens are shown in
Fig. 1. A point spread diagram of the native T1 and ECV
values of all AL amyloidosis patients and healthy sub-
jects are shown in Fig. 2. Patients showed an increase in
native T1 (1438 ± 120 ms vs. 1283 ± 46 ms, P = 0.001)
and ECV (43.9 ± 10.9% vs. 27.0 ± 1.7%, P = 0.001) com-
pared to healthy controls. The intra-observer and inter-
observer variabilities as well as native T1 reproducibility
are shown in Table 3. There were 26 (32%), 18 (22%)
and 38 (46%) patients with no LGE, patchy LGE and
global LGE, respectively. The Kappa coefficient of classi-
fication between the two radiologists was 0.818. The na-
tive T1 and ECV values in subgroups with different LGE
patterns are shown in Fig. 3. Table 4 summarizes the
correlation of native T1, ECV and LGE with clinical,
TTE and other CMR parameters in AL amyloid patients.
Native T1, ECV and LGE showed significant correlation
with each other. Native T1, ECV and LGE showed
significant correlation with NYHA classification, NT-
proBNP and Mayo Stage, and ECV and LGE showed
significant correlation with echocardiographic E/E’.
Univariate analysis showed that both ECV ≥ 44.0% (HR
7.677, 95% CI 2.256–26.128, P= 0.001) and global LGE (HR
5.047, 95% CI 1.971–12.926, P = 0.001) were significantly
prognostic for mortality. Patients categorized by median na-
tive T1 (1456 ms) did not differ significantly in survival
probability (Tarone-Ware P= 0.069) (Fig. 4-a). Patients cate-
gorized by median ECV (ECV< 44.0% and ECV ≥ 44.0%) dif-
fered significantly in survival probability (log rank P = 0.001)
(Fig. 4-b). Patients with no or patchy LGE and global LGE
differed significantly in survival probability (log rank P =
0.001) (Fig. 4-c). We categorized patients into different
subgroups, one with global LGE (n= 38, ECV, 53.4 ± 6.2%)
and the other with no/patchy LGE (n= 44, ECV, 35.83 ±
6.8%). In subgroups with the same LGE pattern, patients
with ECV< 44.0% and ECV ≥ 44.0% differed significantly in
survival probability (log rank P= 0.029), as shown in Fig. 5.
Eight patients (Mayo stage I/II/III/IV, 1/1/3/3; no/
patchy/extensive LGE, 1/3/4) underwent follow-up CMR
scans. The median interval between baseline and follow-
up CMR scans was 12 months. All subjects completed a
standard course of BCD chemotherapy and achieved a
complete response (CR) or very good partial response
(VGPR). For the patient with no LGE, the dynamic
changes of LGE, native T1 and ECV are shown in Fig. 6.
Another patient showed a significant regression of LGE
as well as decreases of native T1 (1658 ms to 1490 ms)
and ECV (62.7% to 51.4%). The other 6 patients showed
no prominent progressions or regressions of LGE, and
different trends of native T1 and ECV (increases in 2 pa-
tients, decreases in 2 patients, and no significant changes
in 2 patients).
Table 2 Univariate and multivariate Cox proportional hazard analysis in all AL amyloidosis patients
Univariate Multivariate Multivariate
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age,


































































0.001 – – 4.804
(1.751–13.179)
0.002
All significantly prognostic factors in univariate analysis were listed. Univariate analysis was not performed for native T1 because the Kaplan-Meier curves crossed
each other (Tarone-Ware, P = 0.069). All clinically and statistically significant variates in univariate analysis were put into the multivariate Cox model, except for log
(cTnI) and log (NT-proBNP), as they were included in Mayo Stage. ECV and LGE were put in separate models because of a correlation ρ of 0.889. Backward
regression was chosen
HR Hazard ratio, CI Confidence interval, NYHA New York Heart Association, cTnI Cardiac Troponin I, NT-proBNP N-terminal pro-B-type natriuretic peptide LVEF Left
ventricle ejection fraction, LGE Late gadolinium enhancement, ECV Extracellular volume
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Multivariate analysis
ECV and LGE were analyzed in separate multivariate
Cox models because they had a correlation value ρ of
0.889. As shown in Table 2, for all AL amyloid patients,
ECV ≥ 44.0% was significantly prognostic for mortality
(HR 7.249, 95% CI 2.039–25.771, P = 0.002) in a multi-
variate Cox model correcting for age (HR 1.082, 95% CI
Fig. 1 LGE image, ECV pseudo-color image, native T1 and ECV bull’s eye plots of AL amyloid patients and healthy control subjects. (1-a, b, c, d) A
healthy control subject displayed no LGE and normal native T1 and ECV at the same slice position. (2-a, b, c, d) A Patient showed no LGE, but
increased native T1 and ECV at the same slice position. (3-a, b, c, d) A Patient showed patchy LGE and increased native T1 and ECV at the same
slice position, especially in the LGE lesion. (4-a, b, c, d) A Patient showed global LGE and increased native T1 and ECV at the same slice position.
LGE = late gadolinium enhancement, ECV = extracellular volume. AHA = American Heart Association
Fig. 2 A point spread diagram of the native T1 and ECV values of all
AL amyloid patients and heathy subjects. ECV = extracellular volume
Table 3 T1 mapping intra-observer and inter-observer variabilities
and native T1 reproducibility showed by Bland-Altman Plot
Bias SD of bias 95% CI
Native T1
Intra-observer variability 1/ms −5.60 16.40 −37.04, 25.84
Intra-observer variability 2/ms 4.20 19.74 −34.49, 42.89
Inter-observer variability/ms 6.12 18.33 −32.88, 44.51
Repeated scan reproducibility/ms 5.45 21.07 −35.86, 46.76
ECV
Intra-observer variability 1/% 0.33 1.44 −2.96, 3.02
Intra-observer variability 2/% 0.27 1.87 −2.41, 3.15
Inter-observer variability 1/% −0.25 1.82 −3.36, 2.80
Repeated pre-contrast T1 mapping scans were performed within one day on
20 volunteers (native T1, 1283 ± 46 ms; LVEF, 65.4 ± 5.7%) and 20 patients
(Mayo Stage I/II/III/IV, n = 4/6/8/2; none/patchy/global LGE, n = 6/4/10; native
T1, 1498 ± 108 ms; LVEF, 58.6 ± 11.1%). For all patients and volunteers, T1
mapping images were independently analyzed by two experienced
radiologists twice. The average value was used. SD Standard deviation, CI
Confidence interval, ECV Extracellular volume
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1.022–1.144, P = 0.006) and septal thickness (HR 1.175,
95% CI 1.035–1.335, P = 0.013). The Harrell’s C statistic
was 0.62. Global LGE (HR 4.804, 95% CI 1.751–13.179,
P = 0.002) was significantly prognostic for mortality in a
multivariate Cox model correcting for NYHA (HR
2.253, 95% CI 1.385–3.666, P = 0.001) and septal thick-
ness (HR 1.130, 95% CI 1.018–1.255, P = 0.022). The
Harrell’s C statistic was 0.60.
Survival analysis separated by therapy status were per-
formed. In the 71 patients without therapy at baseline, 52
(73%) patients were alive at the time of last follow-up. As
shown in Table 5, ECV ≥ 44.0% (HR 4.599, 95% CI 1.493–
14.165, P = 0.008) and global LGE (HR 4.442, 95% CI
1.578–12.389, P = 0.015) were independently prognostic
for mortality, while median native T1 (1456 ms) was not
prognostic for mortality (Tarone-Ware P = 0.108). In the
59 patients received therapy during the follow-up, 46
(78%) patients were alive. ECV ≥ 44.0% (HR 5.926, 95% CI
1.312–26.753, P = 0.021) and global LGE (HR 4.981, 95%
CI 1.369–18.128, P = 0.015) were prognostic for mortality
in univariate Cox model, but not prognostic in any multi-
variate Cox model. Median native T1 was not prognostic
for mortality (Tarone-Ware P = 0.105).
Discussion
In this study, we examined the prognostic value of CMR
ECV, LGE and native T1 in a Chinese population with
AL amyloid. To the best of our knowledge, this is the
first study to concurrently assess the prognostic value of
T1 mapping parameters with LGE in AL amyloid. Our
findings indicate that, while ECV and LGE functioned as
independent prognostic factors for mortality in AL
amyloid patients, native T1 did not display prognostic
value. We also showed that in subgroups with the same
LGE pattern, ECV remained prognostic.
We found AL amyloid patients with no LGE demon-
strated increased native T1 and ECV, highlighting the im-
portance of native T1 and ECV over LGE in early
Fig. 3 Native T1 and ECV values in AL amyloid subgroups with
different LGE patterns. (a) Patients with no LGE showed an increase in
native T1 (1368 ± 75 ms vs. 1283 ± 46 ms, P = 0.032), as compared to
healthy controls. (b) Patients with no LGE showed an increase in ECV
(31.9 ± 5.0% vs. 27.0 ± 1.7%, P = 0.008), as compared to healthy controls.
LGE = late gadolinium enhancement, ECV = extracellular volume
Table 4 Native T1, ECV and LGE correlation with clinical stages,
echocardiographic and other cardiac MR parameters in AL
amyloidosis patients
Native T1 ECV LGE
r or ρ P r or ρ P ρ P
Clinical
NYHA 0.427 0.001 0.686 0.001 0.674 0.001
NT-proBNP 0.351 0.001 0.707 0.001 0.729 0.001
Mayo Stage 0.335 0.002 0.631 0.001 0.671 0.001
Echocardiography
E/A 0.060 0.65 0.309 0.20 0.330 0.20
E/E’ 0.302 0.209 0.488 0.001 0.351 0.006
Cardiac MR
Indexed LVEDV −0.222 0.025 −0.320 0.001 −0.113 0.31
Indexed LVESV −0.078 0.44 0.209 0.036 0.203 0.067
LVEF 0.063 0.93 −0.451 0.001 −0.380 0.001
Left atrium area 0.207 0.037 0.174 0.082 0.197 0.077
Indexed left
ventricle mass
0.360 0.001 0.633 0.001 0.590 0.001
Septal thickness 0.440 0.001 0.626 0.001 0.654 0.001
Native T1 – – 0.605 0.001 – –
LGE 0.420 0.001 0.867 0.001 – –
Correlation between native T1 or ECV with continuous variables was assessed
using Pearson’s r correlation and with categorical variables using Spearman ρ
correlation. Correlation between LGE with other variables was assessed using
Spearman ρ correlation
NYHA New York Heart Association, NT-proBNP N-terminal pro-B-type natriuretic
peptide, MR Magnetic resonance, LVEDV Left ventricle end-diastolic volume,
LVESV Left ventricle end-systolic volume, LVEF Left ventricle ejection fraction,
LGE Late gadolinium enhancement, ECV Extracellular volume
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detection of myocardial involvement in this disorder. In
agreement with other studies [11, 12], we showed that glo-
bal LGE prognostic for mortality. We have also included a
novel finding that subgroups with the same LGE pattern
displayed ECV as a significant prognostic factor. LGE is
the classic and most commonly performed CMR protocol
for myocardial tissue characterization, and a typical pat-
tern of global LGE serves as both diagnostic marker for
cardiac AL amyloid and a prognostic marker for mortality
[11–14]. However, early identification of mild cases of
cardiac AL amyloid and other diffuse infiltrative cardio-
myopathies are easily missed, [15, 16] since the basis of
LGE lesion identification involves demarcating the abnor-
mal tissue amidst normal tissue. It is better to perform T1
mapping scanning together with LGE scanning in AL
amyloid patients, for native T1 and ECV provide
additional diagnostic and prognostic information.
The current study is also the second overall study that
focuses on the prognostic value of T1 mapping parame-
ters in AL amyloid. A previous study demonstrated the
prognostic value of native T1 and ECV for mortality
using a 1.5 T scanner with a shMOLLI sequence [25],
but LGE was not assessed. In this study, using a 3 T
scanner with a MOLLI sequence and found that, regard-
less of disease course and therapy status, ECV was an in-
dependently prognostic factor for mortality with a
similar cut-off value as the previous study.
Moreover, we also found that native T1 did not act as
a prognostic factor, which is controversial with previous
study. Previous studies have shown variations in ECV
values using different scanning sequences including
MOLLI and shMOLLI [24], and variations in native T1
values with different equipment manufacturers, scanning
sequences and undefined physiological status of the pa-
tients [21–23]. Despite the emerging importance of T1
Fig. 4 Kaplan-Meier survival curves for native T1, ECV and LGE. (a)
Patients categorized by median native T1 (1456 ms) did not differ
significantly in survival probability (74.1% vs. 65.7% at the 8th month,
Tarone-Ware P= 0.069). (b) Patients with ECV < 44.0% and ECV≥ 44.0%
differed significantly in survival probability (94.9% vs. 54.6% at the 8th
month, log rank P= 0.001). (c) Patients with no/patchy LGE and global
LGE differed significantly in survival probability (90.7% vs. 56.2% at the
8th month, log rank P = 0.001). LGE = late gadolinium enhancement,
ECV = extracellular volume
Fig. 5 Kaplan-Meier survival curves for ECV in subgroups with the
same LGE pattern. (a) In subgroups with no/patchy LGE (n = 44, ECV,
35.8 ± 6.8%), patients with ECV < 44.0% and ECV≥ 44.0% differed
significantly in survival probability (94.7% vs. 60.0% at the 8th month,
log rank P = 0.029). (b) In subgroups with global LGE (n = 38, ECV,
53.4 ± 6.2%), patients with ECV < 44.0% had a survival probability of
100% and patients with ECV≥ 44.0% had a survival probability of
53.5% at the 8th month. LGE = late gadolinium enhancement,
ECV = extracellular volume




Fig. 6 LGE images, native T1 and ECV bull’s eye plots of a 57-year-old female patient at baseline (1-a,b,c,d), 12-month (2-a,b,c,d) and 24-month
(3-a,b,c,d) follow-up. At baseline, the patient showed no LGE (1-a, b) but elevated native T1 (1-c) and ECV (1-d) values. After chemo-therapy, the
patient has a progressive decline in native T1 and ECV (at baseline, 12-month and 24-month follow-up: 1390 ms, 1371 ms, 1330 ms and 36.3%,
34.4%, 26.4%). At the 12-month follow-up, a new patch of mid-myocardial LGE appeared (2-b: arrow), which was not of typical position and
pattern in AL amyloid, and seemed to regress at the 24-month follow-up. LGE = late gadolinium enhancement, ECV = extracellular volume
Table 5 Univariate and multivariate Cox proportional hazard analysis in patients without therapy at baseline
Univariate Multivariate Multivariate
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age,
























































0.007 – – 4.442
(1.578–12.389)
0.015
All significantly prognostic factors in univariate analysis were listed. Univariate analysis was not performed for native T1 because the Kaplan-Meier curves crossed
each other (Tarone-Ware, P = 0.069). Univariate analysis was not performed for log (cTnI) and log (NT-proBNP), as they were included in Mayo Stage. All clinically
and statistically significant variates in univariate analysis were put into the multivariate Cox model. ECV and LGE were put in separate models because of a
correlation ρ of 0.889. Backward regression was chosen. HR Hazard ratio, CI Confidence interval, NYHA New York Heart Association, LVEF Left ventricle ejection
fraction, LGE Late gadolinium enhancement, ECV Extracellular volume
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mapping, one fundamental issue to be solved is the evi-
dence of a good reproducibility among different institu-
tions. Combining other studies with our current study,
we have shown that ECV is a better T1 mapping param-
eter and, as of now, cannot be replaced by native T1.
ECV calculation requires the administration of an IV
contrast agent. However, renal function impairment is
often seen in AL amyloid patients, since the kidney is
one of the most commonly involved organs [1, 2]. This
and other contraindications for the application of con-
trast agents may limit the use of ECV in this population.
In this situation native T1 in combination with LVEF
and inter-ventricular septum thickness seems to be the
second best approach to detect diffuse myocardial in-
volvement. Our data show that native T1 is not as prog-
nostic as ECV, but still more sensitive than LGE for
myocardial involvement in AL amyloid.
Our study has several limitations. One is the short
follow-up with a median time of 8 months and a relatively
low event proportion of 25.6%. Another limitation is that
we do not have additional parameters to fully characterize
the diastolic function. The third limitation is about the
therapy status of the patients at baseline and during the
follow-up, given the cardiotoxic effects of chemotherapy
agents may be confounding factors. Besides, we found
increased native T1 and ECV values in patients with no
LGE, but only one such patient underwent myocardial
biopsy verifying the result. Thus ours, like most studies in
this area, suffer from the lack of diagnostic pathology.
Conclusion
For myocardial tissue characterization, while LGE is a
classic and most commonly performed parameter, ECV is
a recently developed quantitative CMR parameter. The
current study is the first to compare the prognostic value
of T1 mapping parameters with LGE in AL amyloid. Dur-
ing a short follow-up interval, we showed that both ECV
and LGE were promising prognostic factors for mortality
in AL amyloid. Further, in patients with the same LGE
pattern, ECV remained prognostic, suggesting the merit
of using T1 mapping scanning in conjunction with LGE in
this population. Native T1, however, was found to be not
as equally prognostic as ECV or LGE. Thus, for suspected
AL amyloid patients without contraindications, it is better
to perform contrast enhancement scanning.
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